Reactive arthritis.
Reactive arthritis (ReA) was known as Reiter's disease or Fiessinger-Leroy disease for nearly 100 years. However, during the past 30 years the disease has been known as reactive arthritis, a member of the spondyloarthritis family. Despite knowing the initiating event (infection) and genetic constitution (many patients have HLA-B27) of ReA, a model of interplay between environment and genetics, its pathogenesis is still incompletely known. This review covers the epidemiology, clinical features, treatment, and prognosis of ReA.
Leirisalo-Repo
M
M
Division of Rheumatology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland. marjatta.leirisalo-repo@hus.fi
D000328:Adult; D017677:Age Distribution; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016918:Arthritis, Reactive / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology / Q000382:microbiology*; D004359:Drug Therapy, Combination; D005260:Female; D005387:Finland / Q000453:epidemiology; D015796:HLA-B27 Antigen / Q000276:immunology*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D000091402:Prohibitins; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015796:HLA-B27 Antigen; C000717331:PHB2 protein, human; D000091402:Prohibitins